Epoch 48: Why Biotechs Are Buying Bitcoin

The Strategic Case for BTC in Corporate Treasuries

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. In today’s newsletter, we are discussing the HIGHLY controversial and fascinating trend that’s gaining traction: the adoption of Bitcoin as a treasury asset by biotech companies (and F500). With Acurx Pharmaceuticals, Enlivex Therapeutics, and Hoth Therapeutics leading the charge, this move represents a bold shift in how companies think about preserving cash reserves amidst inflation and economic volatility. For those of you that dont understand Bitcoin we will cover its core features such as, scarcity, inflation-resistant properties, and alignment with innovation. We’ll also examine the broader implications of this strategy, including insights from Michael Saylor’s playbook, the potential impact of the Loomis Bitcoin reserve bill, and how Bitcoin’s scarcity could drive its price higher. At the end we will give our opinion on where we see all this heading in the short term.

If you're not subbed yet click the link below.  Every Thursday we are out with our FREE public/private biotech market update. Sundays are the days we focus on forward looking strategy.  Monday’s are for public equity research.  Tomorrow we will focus on Janux Therapeutics (JANX) which is nearing a pivotal moment with the upcoming release of topline durability data for JANX-007 in relapsed and refractory metastatic colorectal cancer. Given the high investor anticipation and potential market volatility—possibly resulting in stock price fluctuations of ±35%—this development is under close scrutiny.

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Lots to cover this week, let's get started!

Introduction: A Bold Move in Treasury Strategy

Last week, in an unprecedented move, three biotechs—Acurx Pharmaceuticals ($ACXP), Enlivex Therapeutics ($ENLV), and Hoth Therapeutics ($HOT)—announced plans to allocate $1 million each into Bitcoin as part of their treasury strategies. This decision reflects a broader trend where companies are seeking alternative treasury assets, particularly amid economic volatility and rising inflation. Biotechs, which operate in a high-risk, high-reward environment are beginning to explore Bitcoin’s inflation-resistant, decentralized characteristics a logical complement to their innovative ethos. Today we will unpack why this is happening and explore if the time is right for broader biotech adoption.

Strategic Inflation Hedge for Biotechs